Lawmakers urge appeals court to maintain halt on NIH's payment cut plan
A group of members of the House of Representatives told a federal appeals court that the NIH’s planned cap on indirect cost reimbursements disregards Congress’ “exclusive authority to control federal...
View ArticleDraig Therapeutics unveils $140M Series A for neuropsychiatry pipeline
A UK biotech named after the Welsh word for dragon has emerged from stealth with a Phase 2-ready candidate for depression and an oversubscribed Series A fundraise backed by the venture arm of Sanofi. ...
View ArticleActio gets $66M for experimental epilepsy and Charcot-Marie-Tooth treatments
An impressive group of biopharma investors put $66 million into a San Diego startup called Actio Biosciences. The clinical-stage company said Wednesday morning that existing investor Deerfield...
View ArticleEndpoints Livestream: China is still the top conversation starter at BIO
Today on Post-Hoc Live, we’re bringing you interviews live from Boston, where several of our reporters have spent the last few days covering BIO's annual conference. This week, I’m taking over hosting...
View ArticleBavarian Nordic's PRV goes for $160M; Biomea to advance GLP-1 into trials
Plus, news about Camurus and Pelage Pharmaceuticals: Bavarian Nordic to sell its priority review voucher: The Danish pharma company will hand over the PRV to an undisclosed buyer for $160 million ...
View ArticleHumana details plans to grow its primary care clinics
As plenty of clinic chains shut their doors, Humana is growing its fleet of primary care centers, with plans to buy struggling competitors and the remaining stakes in dozens of clinics it co-owns with...
View ArticleTennr raises $101M Series C to fix faxes with AI
Tennr has raised Series C funding at a $605 million valuation to organize faxes in healthcare and automate them, eight months after its last round and a year after its Series A. Because healthcare...
View ArticleScholar Rock reports competitive data for muscle-preserving obesity drug add-on
Scholar Rock’s muscle-building antibody helped patients who are overweight or obese preserve lean mass when they were taking Eli Lilly’s incretin drug Zepbound, the biotech said Wednesday. In a Phase 2...
View ArticleA custom ALS drug could help scale rare disease therapies
In 2020, Jaci Hermstad died at age 26 from a rare and aggressive form of ALS. But her story didn’t end there. A drug that was created just for her, called Jacifusen, has since been ...
View ArticleBioNTech drops indications, stops making cell therapy at Maryland site
BioNTech said it's stopping work on an experimental cell therapy in certain indications, and is winding down cell therapy manufacturing at its Gaithersburg, MD site. “We have made the difficult...
View ArticleBIO's new chair on FDA changes, most favored nation pricing and China
BOSTON — Fritz Bittenbender, the newly-named chair of BIO, is guiding the group through the kind of split-screen experience that has defined the first several months of the second Trump administration....
View ArticleCBER head Prasad adds chief medical and scientific officer to his title
Vinay Prasad, the newly-minted chief of the FDA's biologics center, will now have two additional roles as chief medical and scientific officer, FDA Commissioner Marty Makary told staff in a Wednesday...
View ArticleZealand study shows higher GLP-1/GLP-2 doses may lead to greater weight loss
Zealand Pharma on Wednesday rolled out more Phase 1b data for its experimental GLP-1/GLP-2 drug, showing that higher doses could lead to more weight loss in people who are overweight or obese. The...
View ArticleCompounders lose case over semaglutide shortage
A federal court once again ruled against a trade group for large compounding pharmacies that sought to put Novo Nordisk’s blockbuster obesity drug semaglutide back on the FDA’s shortage list so...
View ArticleGilead gets groundbreaking FDA approval for twice-yearly HIV prevention shot
The FDA has approved Gilead Sciences’ lenacapavir for HIV prevention, making the highly-anticipated twice-yearly shot available to people in the US. Lenacapavir was approved for pre-exposure...
View ArticleGrail shares jump on study results for cancer test
Grail's shares jumped on Wednesday after the company reported what it called encouraging results in its cancer detection test. The company, which aims for early detection of multiple cancers in a blood...
View ArticleFDA's top cell and gene therapy leaders leave agency
The FDA's top leadership in its cell and gene therapy division have been let go, sources told Endpoints News, in the latest shakeup at the agency that has seen significant numbers of staff and other ...
View ArticleRoche's venture arm chief to step down in 2026; AstraZeneca obesity leader...
→ Carole Nuechterlein said on LinkedIn that she is retiring as head of the Roche Venture Fund “next spring.” Nuechterlein has held this position since 2001. Roche’s venture arm recently participated in...
View ArticleEnzene, Veranova separately unveil expansions; Lotte's new ADC client
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Enzene announced it plans to expand its biologics production facility...
View ArticleFDA OKs new label expansions for Dupixent and Incyte's Monjuvi
Plus, news about Novartis' Mariana Oncology: FDA approves Dupixent in rare autoimmune disease: The approval is for bullous pemphigoid, a condition in which the immune system attacks ...
View Article